Library Open Repository

Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis

Downloads

Downloads per month over past year

Ding, C and Li, Q and Xiong, ZY and Zhou, AW and Jones, G and Xu, SY (2003) Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis. Clinical & Experimental Immunology, 132 (3). pp. 416-423. ISSN 0009-9104

[img] PDF
ClinExpImmunol.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.

[img]
Preview
PDF (Author Version)
Ding_REV.pdf | Download (100kB)
Available under University of Tasmania Standard License.

Abstract

The objective of this study was to investigate the effect of the oral administration of type II collagen (CII) on pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis (AA). Sprague-Dawley rats were fed with bovine CII either before immunization with Complete Freund's adjuvant (CFA) or after initiation of arthritis. Hind paw secondary swelling was measured and synoviocytes were harvested. Sera from portal vein of oral tolerized rats were collected and in vitro synoviocytes culture or synoviocytes-Peyer's Patches (PP) cells coculture system were developed. Interleukin (IL)-1 activity was measured by a mouse thymocyte activation assayed by MTT dye reduction and tumour necrosis factor (TNF) activity was measured by an L929 cytotoxicity bioassay. Nitric oxide (NO) and malondialdehyde (MDA) levels were measured by biochemical methods. We found that feeding with CII (5, 50 and 500 ug/kg) for 7 days before immunization significantly suppressed hind paw secondary swelling measured at day 16, 20, 24 and 28 (all P< 0.01) and pro-inflammatory mediator (IL-1, TNF, NO and MDA) production by synoviocytes (all P< 0.01) in rats with AA. Feeding with CII (5, 50 and 500 ug/kg) for 7 days after initiation of arthritis had a similar effect. CII (1, 10, 100 ug/ml) had no effect on IL-1 and TNF production by synoviocytes in vitro, but CII 10 ug/ml suppressed IL-1 and TNF production by synoviocytes-PP cells coculture system (P < 0.01), which was antagonized by anti-TGF-beta antibody (10 ug/ml) (P < 0.01). Portal serum (1 : 10) from oral tolerized rats suppressed IL-1 and TNF production by synoviocytes (P < 0.01), which was also antagonized by anti-TGF-beta antibody (10 ug/ml) (P < 0.01). We conclude that oral administration of CII had prophylactic and therapeutic effects on AA and over-production of IL-1, TNF, NO and MDA by synoviocytes was suppressed. Bystander active suppression may be the main mechanism of oral CII in the suppression of synoviocyte function.

Item Type: Article
Keywords: type II collagen, inflammatory mediator, oral tolerance, arthritis
Journal or Publication Title: Clinical & Experimental Immunology
Page Range: pp. 416-423
ISSN: 0009-9104
Identification Number - DOI: 10.1046/j.1365-2249.2003.02167.x
Additional Information: The definitive version is available at www.blackwell-synergy.com. Visit - http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2249.2003.02167.x
Date Deposited: 30 Apr 2007
Last Modified: 18 Nov 2014 03:14
URI: http://eprints.utas.edu.au/id/eprint/945
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page